Silent Crohn's Disease: Asymptomatic Patients with Elevated C-reactive Protein Are at Risk for Subsequent Hospitalization

Inflammatory Bowel Diseases

Volumn 21, Issue 10, 2015, Pages 2254-2261

  Click, Benjamin ^a   Vargas, Eric J ^a,b,c   Anderson, Alyce M ^a   Proksell, Siobhan ^a   Koutroubakis, Ioannis E ^a   Ramos Rivers, Claudia ^a   Hashash, Jana G ^a   Regueiro, Miguel ^a   Watson, Andrew ^a   Dunn, Michael A ^a   Schwartz, Marc ^a   Swoger, Jason ^a   Baidoo, Leonard ^a   Barrie, Arthur ^a   Binion, David G ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

C reactive protein; Crohn's disease; disease monitoring; hospitalization

Indexed keywords

C REACTIVE PROTEIN;

ADULT; ARTICLE; COHORT ANALYSIS; CROHN DISEASE; DIAGNOSTIC TEST; FEMALE; FOLLOW UP; HARVEY BRADSHAW CD SCORE; HOSPITALIZATION; HUMAN; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; SCORING SYSTEM; SHORT INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE SCORE; SURVIVAL; TERTIARY CARE CENTER; ASYMPTOMATIC DISEASE; BLOOD; KAPLAN MEIER METHOD; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTOR; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA;

ADULT; ASYMPTOMATIC DISEASES; C-REACTIVE PROTEIN; CROHN DISEASE; FEMALE; HOSPITALIZATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES;

EID: 84942250189     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000516     Document Type: Article

References (21)

1. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009; 361:2066-2078.
2. Solem CA, Loftus EV Jr, Tremaine WJ, et al. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:707-712.
3. Burri E, Beglinger C, Lehmann FS. Monitoring of therapy for inflammatory bowel disease. Digestion. 2012;86(suppl 1):1-5.
4. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet. 1980;1:514.
5. Vermeire S, Schreiber S, Sandborn WJ, et al. Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity. Clin Gastroenterol Hepatol. 2010;8:357-363.
6. Irvine EJ, Zhou Q, Thompson AK. The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial. Am J Gastroenterol. 1996;91: 1571-1578.
7. Jowett SL, Seal CJ, Barton JR, et al. The short inflammatory bowel disease questionnaire is reliable and responsive to clinically important change in ulcerative colitis. Am J Gastroenterol. 2001;96:2921-2928.
8. Ananthakrishnan AN, Weber LR, Knox JF, et al. Permanent work disability in Crohn's disease. Am J Gastroenterol. 2008;103:154-161.
9. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55:426-431.
10. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(suppl A):5-36.
11. Henrisksen M, Jahnsen J, Lygren I, et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut. 2008;57:1518-1523.
12. Filik L, Dagli U, Ulker A. C-reactive protein and monitoring the activity of Crohn's disease. Adv Ther. 2006;23:655-662.
13. Boirivant M, Leoni M, Tariciotti D, et al. The clinical significance of serum C reactive protein levels in Crohn's disease. Results of a prospective longitudinal study. J Clin Gastroenterol. 1988;10:401-405.
14. Halpin SJ, Ford AC. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2012;107:1474-1482.
15. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362: 1383-1395.
16. Gottlieb SO, Weisfeldt ML, Ouyang P, et al. Silent ischemia as a marker for early unfavorable outcomes in patients with unstable angina. N Engl J Med. 1986;314:1214-1219.
17. Gottlieb SO, Weisfeldt ML, Ouyang P, et al. Silent ischemia predicts infarction and death during 2 year follow-up of unstable angina. J Am Coll Cardiol. 1987;10:756-760.
18. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2010;105:162-169.
19. Sipponen T, Savilahti E, Kolho KL, et al. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis. 2008;14: 40-46.
20. Sox HC, Greenfield S. Comparative effectiveness research: a report from the Institute of Medicine. Ann Intern Med. 2009;151:203-205.
21. Luce BR, Kramer JM, Goodman SN, et al. Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change. Ann Intern Med. 2009;151:206-209.